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Abstract: The numbers of obese people and diabetic patients are ever increasing. Obesity 
and diabetes are high-risk conditions for chronic diseases, including certain types of cancer, 
such as colorectal cancer (CRC). The aim of this study was to develop a novel animal 
model in order to clarify  the pathobiology of  CRC development in obese and diabetic 
patients. We developed an animal model of obesity and colorectal cancer by breeding the 
C57BL/KsJ-db/db (db/db) mouse, an animal model of obesity and type II diabetes, and the 
C57BL/6J-Apc
Min/+  (Min/+)  mouse,  a  model  of  familial  adenomatous  polyposis.  At  15 
weeks of age, the N9 backcross generation of C57BL/KsJ-db/db-Apc
Min/+ (db/db-Min/+) 
mice developed an increased incidence and multiplicity of adenomas in the intestinal tract 
when compared to the db/m-Min/+ and m/m-Min/+ mice. Blood biochemical profile showed 
significant increases in insulin (8.3-fold to 11.7-fold), cholesterol (1.2-fold to 1.7-fold), and 
triglyceride (1.2-fold to 1.3-fold) in the db/db-Min/+ mice, when compared to those of the 
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db/m-Min/+  and  m/m-Min/+  mice.  Increases  (1.4-fold  to  2.6-fold)  in  RNA  levels  of 
insulin-like growth factor (IGF)-1, IRF-1R, and IGF-2 were also observed in the db/db-
Min/+  mice.  These  results  suggested  that  the  IGFs,  as  well  as  hyperlipidemia  and 
hyperinsulinemia, promoted adenoma formation in the db/db-Min/+ mice. Our results thus 
suggested that the db/db-Min/+ mice should be invaluable for studies on the pathogenesis of 
CRC in obese and diabetes patients and the therapy and prevention of CRC in these patients. 
Keywords:  C57BL/KsJ-db/db;  C57BL/6J-Apc
Min/+;  Type  2  diabetes  mellitus;  colon 
carcinogenesis; animal model 
 
1. Introduction 
Epidemiological  studies  have  shown  that  obesity  and  diabetes  mellitus  may  be  one  of  the  
risk factors for colorectal cancer (CRC) development [1,2]. To date the underlying mechanisms of  
how obesity and diabetes promote colon carcinogenesis remain unknown, although insulin-resistance 
and hyperinsulinemia are proposed to be responsible for the risk factor [3]. Excess body weight is a 
major  determinant  for  the  development  of  insulin  resistance  with  associated  hyperinsulinaemia  
and  hyperglycemia,  and  further  leads  to  CRC  development  [4].  Certainly,  insulin  resistance  and 
hyperinsulinaemia are key biological mechanisms underlying the relationship between adiposity and 
tumor development [5]. Recently, the anti-diabetic drug, metformin, in addition to reduction of insulin 
resistance  has  shown  anti-tumor  properties  [6],  and  is  considered  as  a  drug  to  prevent  and  treat  
obesity-related  cancers,  including  CRC  [7].  The  pathophysiological  and  biological  mechanisms 
underpinning  the  associations  between  excess  body  weight/obesity,  type  2  diabetes,  and  CRC  are 
proposed,  and  insulin  resistance  is  at  the  heart  of  the  matter  [8].  However,  there  are  several  other 
candidate  systems,  including  insulin-like  growth  factors  (IGF),  adipocytokines,  and  inflammatory 
cytokines [9]. One such hypotheses is the role of insulin-IGF axis, where chronic hyperinsulinemia is 
associated with decreased concentrations of IGF-binding protein1 (IGFBP-1) and IGFBP-2, leading to 
increased availability of IGF-I and concomitant changes in the cellular environment that favor tumor 
development. Indeed, inhibition of the activation of the  IGF/IGF-1R axis resulted in suppression of 
colonic premalignant lesions in an obesity-associated colon cancer model, which was also associated 
with hyperlipidemia, hyperinsulinemia, and hyperleptinemia [10]. However, hyperinsulinemia is also 
associated with alterations in related molecular systems (sex steroid hormones and adipocytokines). In 
this context, novel researches using appropriate animal models are needed to investigate the detailed 
mechanisms.  We  previously  reported  that  C57BL/KsJ-db/db  mice  with  hyperleptinemia  and 
hyperinsulinemia  are  highly  susceptible  to  azoxymethane  (AOM)-induced  colon  carcinogenesis. 
C57BL/KsJ-db/db mice received AOM developed high frequency of premalignant lesions [11,12], and 
the  mice  are  useful  for  studies  for  identifying  chemopreventive  agents  against  obesity/diabetes-
assosiated colon carcinogenesis [13,14]. Min/+ mice [15], known to develop a number of adenomas by 
the same mechanism or process as seen in humans, have frequently been used as an animal model of 
familial adenomatous polyposis (FAP) for investigation of carcinogenesis, prevention, and therapy of 
CRC [16–21]. Int. J. Mol. Sci. 2011, 12                       
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In the current study, we aimed to develop a spontaneous animal model of obesity with adenoma 
formation in the intestinal tract in order to investigate obesity-associated events in obesity-associated 
intestinal  tumorigenesis  and  prevent  spontaneous  intestinal  tumor  development  in  the  model.  The 
model was developed by breeding db/m mice with Min/+ mice and then backcrossing of db/m mice with 
the offsprings born from both strains of mice. The db/db-Min/+ mice obtained will give us the important 
implications for further exploration of the possible underlying events that affect the positive association 
between CRC and chronic diseases, obesity and diabetes. Our main goal was to assess the involvement 
of obesity-associated events, such as hyperinsulinemia, in intestinal carcinogenesis in vivo.  
2. Materilas and Methods 
2.1. Animals 
C57BL/KsJ-db+/+m (db/m) and C57BL/6J-Apc
Min/+ (Min/+) mice were purchased from the Japan 
SLC, Inc. (Shizuoka, Japan) and from the Jackson Laboratory (Bar Harbor, ME), respectively. They 
were bred and genotyped in our facility for the project. In brief, after the db/m females were mated 
with a db/m-Min/+ male, we finally obtained three mouse strains, the db/db-Min/+, the db/m-Min/+, 
and  the  m/m-Min/+  mice  at  the  N9  backcross  generation  by  backcrossing  db/m  mice  with  the 
offsprings born from the mating between the db/m mice and the Min/+ mice (Figure S1), The Apc gene 
was detected by polymerase chain reaction (PCR), while the db/m gene was recognized by the body 
shape and coat color of mice. 
Mice used for the study were maintained in the well-controlled room with a high-efficiency particulate 
air (HEPA) filter, a 12 h lighting (7:00–19:00), 25 ± 2 °C room temperature, and 55 ± 15% humidity. 
Mice  (3–6  mice/cage)  were  housed  in  polycarbonate  cages  measuring  W225  ×  D338  ×  H140  mm  
(Japan  CLEA,  Inc.,  Tokyo,  Japan)  with  the  floor  covered  with  a  sheet  of  roll  paper  (Japan  SLC, 
Hamamatsu  City,  Japan).  MF  (Oriental  Yeast  Co.,  Ltd.,  Tokyo,  Japan)  was  used  as  a  basal  diet 
throughout the study. Groundwater that was chlorine-treated and subjected to ultraviolet disinfection 
was  used  as  drinking  water  in  a  bottle.  We  fully  complied  with  the  “Guidelines  Concerning 
Experimental  Animals”  issued  by  the  Japanese  Association  for  Laboratory  Animal  Science  and 
exercised due consideration so as not to cause any ethical problem. 
2.2. Experimental Procedure 
After weaning at 4 weeks of age, a total of 94 mice aged 5 weeks were used in the study. They 
included 18 males and 13 females of db/db-Min/+ mice, 23 males and 19 females of db/m-Min/+ mice 
and 11 males and 10 females of m/m-Min/+ mice, at 15 weeks of age, the mice were weighed and 
measured  their  lengths  for  BMI  calculation,  and  thereafter  underwent  blood  withdrawal  from 
abdominal aorta under anesthetic and intestinal evisceration for counting intestinal adenomas.  
2.3. Pathological and Immunohistochemical Analyses 
In addition to the macroscopic examination, the volume of colonic tumors was determined. The 
mean volumes (mm
3) of colonic tumors were calculated by the formula, (a) × (b) × (b)/2 where (a) and 
(b) were major axis and minor axes, respectively. After careful macroscopic observation, the small and Int. J. Mol. Sci. 2011, 12                       
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large intestines were fixed in 10% buffered formalin and paraffin-embedded tissue blocks of whole 
intestine were made. These tissues were subjected to hematoxylin and eosin (H & E) staining for 
histopathology. In addition, immunohistochemistry of β-catenin and IGF-1R were performed using the 
labeled streptavidin-biotin method (LSAB kit; DAKO, Glostrup, Denmark), as previously described. 
Anti-β-catenin antibody (1:1,000 final dilution) obtained from Transduction Laboratories (catalog no. 
610154; San Jose, CA, USA) and anti-IGF-1R antibody (1:100 final dilution) purchased from Santa 
Cruz  Biotechnology,  Inc.  (sc-7907;  Santa  Cruz,  CA,  USA)  were  applied  as  primary  antibodies. 
Negative control sections were immunostained without the primary antibodies. 
2.4. Blood Chemistry 
At 15 weeks of age, blood samples (0.5–1.0 mL/mouse) were collected for determination of total 
cholesterol, triglyceride and glucose by a simple measurement device (DRICHEM Fujifilm Medical Co., 
Ltd., Tokyo, Japan). The concentration of blood insulin was measured by the LBIS insulin measuring kit 
for mice (Shibayagi Co., Ltd., Gunma, Japan). 
2.5. RNA Extraction and Quantitative Real-Time RT-PCR Analysis 
A quantitative real-time RT-PCR analysis was carried. Total RNA was isolated from the scraped 
colonic mucosa of the male mice (n = 6 from each strain) using the RNAqueous-4PCR kit (Ambion 
Applied Biosystems, Austin, TX, USA). The cDNA was synthesized from 0.2 µg total RNA using the 
SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA). The primers used for 
the  amplification  of  IGF-1,  IGF-2,  and  IGF-1R  specific  genes  were  as  follows:  IGF-1  forward,  
5-CTGGACCAGAGACCCTTTGC-3  and  reverse,  5-GGACGGGGACTTCTGAGTCTT-3;  IGF-2 
forward,  5-GTGCTGCATCGCTGCTTAC-3  and  reverse,  5-ACGTCCCTCTCGGACTTGG-3;  and 
IGF-1R forward, 5-GTGGGGGCTCGTGTTTCTC-3 and reverse, 5-GATCACCGTGCAGTTTTCCA-3. 
Real-time  PCR  was  done  in  a  LightCycler  (Roche  Diagnostics  Co.,  Indianapolis,  IN,  USA)  with 
SYBR Premix Ex Taq (TaKaRa Bio, Shiga, Japan). The expression levels of the IGF-1, IGF-2, and 
IGF-1R genes were normalized to the β-actin gene expression level. 
2.6. Statistical Analysis 
Measurements are expressed as the mean value ± standard deviation (Mean ± SD), and differences 
if present were compared by one-way analysis of ANOVA and Tukey-Kramer’s multiple comparison’s 
test. The incidences of intestinal tumors were compared by Fisher’s exact probability test. The results 
were considered statistically significant if the p values were <0.05. 
3. Results 
3.1. General Observations 
As shown in Figure 1, the mean body weights of the db/db-Min/+ mice, either males (Figure 1(A)) 
or  females  (Figure  1(B)),  were  significantly  heavier  even  at  the  age  of  5  weeks  than  that  of  the  
db/m-Min/+ and m/m-Min/+ mice. The differences continued up to 15 weeks of age. The mean body Int. J. Mol. Sci. 2011, 12                       
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weights of males and females of db/m-Min/+ mice were significantly higher than that of the m/m-Min/+ 
mice in either sex at 5 weeks of age, and this trend continued until 15 weeks of age. Table 1 summarizes 
the body length, body weight, and body mass index (BMI) at 15 weeks of age. The BMIs of the  
db/db-Min/+ mice (0.62 ± 0.04 in males and 0.63 ± 0.08 in females, p < 0.001 for each comparison) 
were significantly greater than those of the db/m-Min/+ (0.35 ± 0.03 in males and 0.30 ± 0.03 in 
females) and m/m-Min/+ mice (0.34 ± 0.05 in males and 0.27 ± 0.03 in females). 
Figure 1. Body weight gains during the study: (A) males and (B) females. 
 
(A)  (B) 
Table 1. Body weight, body length and BMI of mice at 15 weeks of age. 
Gender 
Genotype  No. of mice 
examined 
Body weight 
(g) 
Body length (cm)  BMI 
(g/cm
2)  db/db type  Apc
Min/+ type 
Males 
db/db  Min/+  18  54.7 ± 3.9 
a,b  9.38 ± 0.30 
c  0.62 ± 0.04 
b 
db/m  Min/+  23  30.2 ± 2.3 
d  9.23 ± 0.38  0.35 ± 0.03 
e 
m/m  Min/+  11  27.3 ± 3.2 
f  9.00 ± 0.30  0.34 ± 0.05 
f 
Females 
db/db  Min/+  13  54.2 ± 6.4 
g  9.30 ± 0.24 
h  0.63 ± 0.08 
g 
db/m  Min/+  19  24.5 ± 1.8  9.13 ± 0.33  0.30 ± 0.03 
m/m  Min/+  10  20.8 ± 1.8  8.75 ± 0.23  0.27 ± 0.03 
a Mean ± SD; 
b Significantly different from the db/m-Min/+ and m/m-Min/+ males (p < 0.001);  
c Significantly different from the m/m-Min/+ males (p < 0.05); 
d Significantly different from the 
db/m-Min/+ females (p < 0.001); 
e Significantly different from the db/m-Min/+ females (p < 0.01); 
f Significantly different from the m/m-Min/+ females (p < 0.01); 
g Significantly different from the 
db/m-Min/+ and m/m-Min/+ females (p < 0.001); 
h Significantly different from the m/m-Min/+ 
females (p < 0.01). 
3.2. Serum Levels of Glucose, Total Cholesterol, Triglyceride and Insulin in Experimental Mice 
The blood concentrations of glucose, total cholesterol, triglyceride, and insulin in the db/db-Min/+, 
db/m-Min/+, and m/m-Min/+ at 15 weeks of age are listed in Table 2. The measures of the db/db-Min/+ 
mice were higher than that of the db/m-Min/+ or m/m-Min/+ mice (0.001 < p < 0.05). However, the 
values of the db/m-Min/+ and m/m-Min/+ mice of either sex were comparable. Int. J. Mol. Sci. 2011, 12                       
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Table 2. Serum levels of glucose, total cholesterol, triglyceride, and insulin of mice at  
15 weeks of age. 
Gender 
Genotype  No. of mice 
examined 
Glucose 
(mg/dL) 
Total cholesterol 
(mg/dL) 
Triglyceride 
(mg/dL) 
Insulin 
(ng/dl)  db/db type  Apc
Min/+ type 
Males 
db/db  Min/+  18  250.6 ± 35.6 
a,b  161.8 ± 28.7 
b  193.1 ± 14.8 
c  3.3 ± 1.4 
b 
db/m  Min/+  23  185.7 ± 27.6 
d  109.4 ± 13.1  162.6 ± 27.6  0.4 ± 0.2 
m/m  Min/+  11  187.0 ± 21.8 
e  96.1 ± 13.0  165.2 ± 21.5  0.3 ± 0.1 
Females 
db/db  Min/+  13  226.2 ± 28.7 
f  145.1 ± 18.5 
g  215.0 ± 38.0 
h,i  3.5 ± 1.1 
f 
db/m  Min/+  19  181.6 ± 24.5  119.1 ± 12.5  182.3 ± 29.8  0.3 ± 0.1 
m/m  Min/+  10  195.0 ± 20.4  115.3 ± 10.3  170.9 ± 18.2  0.3 ± 0.1 
a Mean ± SD; 
b Significantly different from the db/m-Min/+ and m/m-Min/+ males (p < 0.001);  
c Significantly different from the db/m-Min/+ males (p < 0.01); 
d Significantly different from the 
db/m-Min/+ females (p < 0.01); 
e Significantly different from the m/m-Min/+ females (p < 0.01);  
f Significantly different from the db/m-Min/+ and m/m-Min/+ females (p < 0.001); 
g Significantly 
different from the m/m-Min/+ females (p < 0.01); 
h Significantly different from the db/m-Min/+ 
females (p < 0.05); 
i Significantly different from the m/m-Min/+ females (p < 0.01). 
3.3. Tumors in the Intestinal Tract 
Intestinal nodular tumors were observed in three strains of mice of each sex. As shown in Table 3, 
the total numbers of tumors, histopathologically tubular adenomas (Figure 2(A)), in small and large 
intestine of the db/db-Min/+ mice (60.5 ± 14.6 in males and 57.8 ± 12.7 in females, p < 0.001 for each 
comparison) were significant larger than the db/m-Min/+ mice (32.1 ± 7.5 in males and 32.6 ± 5.9  
in females) and m/m-Min/+ mice (30.5 ± 7.7 in males and 30.9 ± 6.3 in females). The values of the 
db/m-Min/+  mice  and  m/m-Min/+  mice  were  comparable.  The  mean  numbers  of  small  intestinal 
tumors of the db/db-Min/+ mice of both sexes at the age of 15 weeks were also significantly greater than 
that of the db/m-Min/+ and m/m-Min/+ mice (p < 0.001). The incidence and multiplicity of colonic 
adenomas of the male and female db/m-Min/+ mice were greater than those of the db/m-Min/+ and  
m/m-Min/+ mice, and significant differences in the incidence were observed between the db/db-Min/+ 
and  db/m-Min/+  (p  <  0.005)  or  m/m-Min/+  males  (p  <  0.005),  but  not  between  the  females. 
Histopathology of intestinal tumors developed in three strains of mice did not significantly differ. 
There were no significant differences in proliferation activities and apoptotic index in the tumor cells 
among three strains of mice (data not shown). 
The mean volumes (mm
3) of colon tumors were 11.95 ± 11.70 (n = 31) in the db/db-Min/+ mice, 
13.63 ± 8.78 (n = 12) in the db/m-Min/+ mice, and 15.52 ± 13.67 (n = 10) in the m/m-Min/+ mice, and 
the values did not significantly differ among three strains of both sexes. Int. J. Mol. Sci. 2011, 12                       
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Table 3. Multiplicity (no. of tumors/mouse) and incidence of intestinal tumors (adenomas) 
of mice at 15 weeks of age. 
Gender 
Genotype 
No. of mice 
examined 
Total number of 
adenomas/mouse 
(incidence) 
Small intestine 
(incidence) 
Colon 
(incidence)  db/db type  Apc
Min/+ type 
Males 
db/db  Min/+  18 
60.5 ± 14.6 
a,b  
(18/18, 100%) 
58.8 ± 13.7 
b  
(18/18, 100%) 
1.7 ± 2.6  
(12/18, 66.7% 
c) 
db/m  Min/+  23 
32.1 ± 7.5  
(23/23, 100%) 
31.6 ± 6.7  
(23/23, 100%) 
0.6 ± 1.2  
(5/23, 21.8%) 
m/m  Min/+  11 
30.5 ± 7.7  
(11/11, 100%) 
29.5 ± 6.1  
(11/11, 100%) 
0.9 ± 2.1  
(3/11, 27.3%) 
Females 
db/db  Min/+  13 
57.8 ± 12.7 
d 
(13/13, 100%) 
58.6 ± 12.3 
d 
(13/13, 100%) 
1.2 ± 1.5  
(7/13, 53.8%) 
db/m  Min/+  19 
32.6 ± 5.9  
(19/19, 100%) 
32.4 ± 5.9  
(19/19, 100%) 
0.2 ± 0.4  
(4/19, 21.1%) 
m/m  Min/+  10 
30.9 ± 6.3  
(10/10, 100%) 
30.7 ± 6.3  
(10/10, 100%) 
0.2 ± 0.4  
(2/10, 20.0%) 
a  Mean  ±  SD; 
b  Significantly  different  from  the  db/m-Min/+  and  m/m-Min/+  males  (p  <  0.001);  
c Significantly different from the db/m-Min/+ and m/m-Min/+ males (p < 0.005); 
d Significantly different 
from the db/m-Min/+ and m/m-Min/+ females (p < 0.001). 
Figure 2. Histopathology of a colonic tumor developed in db/db-Min/+ mice. The tumor is 
histopathologically diagnosed as a tubular adenoma. Immunohistochemistry of β-catenin 
and IGF-1R in the tumor shows positive reaction of β-catenin in their cell membrane and 
cytoplasm and IGF-1R in their cytoplasm. Bars = 50 µm. (A) H & E stain; (B) β-catenin 
immunohistochemistry; and (C) IGF-1R immunohistochemistry. 
 Int. J. Mol. Sci. 2011, 12                       
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Figure 2. Cont. 
   
3.4. Expression Levels of IGF-1, IGF-2, and IGF-1R mRNAs 
The  expression  levels  of  IGF-1,  IGF-2,  and  IGF-1R  mRNAs  in  the  colonic  mucosa  of  the  
db/db-Min/+, db/m-Min/+ and m/m-Min/+ mice. As illustrated in Figure 3, the db/db-Min/+ mice 
showed significant increased mRNA levels of IGF-1, IRF-1R, and IGF-2 (1.4-fold to 2.6-fold increase), 
when compared to the db/m-Min/+ or m/m-Min/+ mice. 
Figure 3. mRNA expression of IGF-1, IGF-2, and IGF-1R in the colonic mucosa of three 
strains of male mice (n = 6 from each strain). 
 
3.5. Immunohistochemistry of β-Catenin and IGF-IR in the Colonic Tumors 
Immunohistochemical  expression  of  β-catenin  was  accumulated  in  the  nucleus  and  cytoplasm  
of  the  colonic  adenoma  cells  (Figure  2(B))  developed  in  three  strains  of  mice.  IGF-IR  was 
immunohistochemically  expressed  in  the  cytoplasm  and  cell  membrane  of  the  adenoma  cells  
(Figure 2(C)) and the sustainability did not significantly differ among adenomas developed in three 
strains of mice. Also, adenomas developed in small intestine shows similar expression of β-catenin and 
IGF-1R (data not shown).  Int. J. Mol. Sci. 2011, 12                       
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4. Discussion 
In  the  current  study,  we  generated  three  mouse  strains,  the  db/db-Min/+,  db/m-Min/+,  and  
m/m-Min/+ mice, by breeding db/m mice with the Min/+ mice, and then backcrossing of the db/m 
mice  with  the  offsprings  born  from  both  strains  of  mice.  All  three  strains  developed  intestinal 
adenomas and the number of tumors of either small intestine or colon in the db/db-Min/+ mice was 
greater than that of the db/m-Min/+ and m/m-Min/+ mice. The db/db-Min/+ mice were heavier than 
db/m-Min/+ and m/m-Min/+ mice. As expected, our findings were in accordance with our previous 
report showing that C57BL/KsJ-db/db obese mice were highly susceptible to AOM-induced colon 
carcinogenesis. In addition, the db/db-Min/+ mice had hyperinsulinemia, diabetes, and hyperlipidemia. 
Unexpectedly,  development  of  colonic  tumors  including  adenocarcinoma  was  not  remarkable,  
but the number was slightly greater than that (0.5–1.1 colon tumors/mouse) described in previous 
reports  [22,23].  The  findings  suggest  that  induction  of  a  number  of  colonic  tumors  including 
adenocarcinoma needs other either intrinsic or external stimuli [24]. mRNA levels of IGF-1, IRF-1R, 
and  IGF-2  in  the  colonic  mucosa  of  the  db/db-Min/+  mice  were  greater  than  the  db/m-Min/+  or  
m/m-Min/+ mice. Immunohistochemically, the expression of β-catenin was accumulated in the nucleus 
and  cytoplasm  of  small  and  large  intestinal  adenoma  cells,  and  IGF-1R  in  the  cytoplasm.  These 
findings  suggest  that  up-regulation  of  the  expression  of  IGFs  and  the  receptor  might  play  a  
role  in  intestinal  tumorigenesis  [25],  and  that  hyperinsulinemia  could  affect  receptor-mediated 
signaling [10,11,26–28] in the db/db-Min/+ mice. 
There is accumulating evidence suggesting that hyperinsulinemia and hyperlipidemia are involved 
in colon carcinogenesis in obese and diabetic rodents [29,30]. Several epidemiological studies indicate 
that diabetic patients with hyperinsulinemia have increased risk for CRC [27,31–35]. An experimental 
animal  study  also  showed  that  continuous  injections  of  insulin  promote  AOM-induced  colon 
carcinogenesis in rats [36]. Hence, it seems likely that hyperinsulinemia in the db/db-Min/+ mice 
enhanced the development of intestinal adenomas in the current study. Regarding the mode of action, 
IGF-1 pathway plays a role in insulin-related tumor promotion in the colon. IGF-1 binds to the IGF-1R, 
activates a signal cascade, and triggers cell proliferation in several tissues, including colon [10,27,31]. 
Because of the homology with the insulin receptor, insulin at supra-physiological levels also binds to 
and  activates  the  IGF-1R  [37].  Furthermore,  hyperinsulinemia  was  shown  to  indirectly  increase 
bioavailability  of  IGF-1  by  regulating  the  expression  levels  of  IGF-binding  proteins  [38,39].  Our 
findings that IGF-1R expression was immunohistochemically up-regulated in the intestinal adenomas 
were in  accordance with other studies showing that the  IGF-1R is overexpressed in human CRC. 
Accordingly,  it  is  possible  that  hyperinsulinemia  in  the  db/db-Min/+  mice  activates  the  signaling 
cascades involving the IGF-1R, resulting in a proliferative response.  
In this study, we noticed hypelipidemia in the db/db-Min/+ mice, which is also a risk factor of 
human  CRC  development  [40–43].  Experimentally,  hyperlipidemia  was  found  in  intestinal 
carcinogenesis  models  with  obese  [14]  and  Min/+  mice  [44].  Improvement  of  hyperlipidemia  by 
certain drugs or natural compounds resulted in reduction and prevention of intestinal carcinogenesis in 
these models [10,13,14,22,23,28,44–47]. Thus, hyperlipidemia also contributes to a high incidence of 
spontaneous intestinal tumors in the db/db-Min/+ mice. Int. J. Mol. Sci. 2011, 12                       
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In the current study, we observed that the congenic db/db-Min/+ mice increase intestinal tumors 
compared  to  either  transgenic  counterpart.  However,  the  volume  of  intestinal  tumors  did  not 
significantly differ among the db/db-Min/+, db/m-Min/+ and m/m-Min/+ mice. Since differences in 
the indices of proliferation and apoptosis in the tumors were not observed among the three strains of 
mice (data not shown), there may be other factors that affect the growth of intestinal tumors. Recently  
Endo et al. [48] reported that the growth of colorectal tumors is dramatically inhibited in the db/db 
mice. Therefore, the leptin signaling might be important for colorectal tumor growth. 
In conclusion, our findings described here indicate that the db/db-Min/+ mice with hyperinsulinemia 
and  hyperlipidemia  developed  many  intestinal  adenoma,  and  the  number  was  much  greater  than  
the  db/m-Min/+  and  m/m-Min/+  mice.  The  results  observed  were  considered  to  occur  through 
hyperinsulinemia  and  modulation  of  insulin-IGF  axis.  Since  several  biological  events  other  than 
hyperinsulinemia/hyperlipidemia  are  also  reported  to  be  involved  in  the  association  between 
obesity/excess body weight, insulin resistance, and CRC development, such as chronic inflammation 
(inflammatory cytokines), glucose toxicity, advanced glycation end products product metabolism, and 
adipocytokies, further studies will be necessary to reveal the specific determinants that are responsible 
for the correlation between obesity and/or diabetes and colon carcinogenesis. Our db/db-Min/+ mice 
could be used for such studies. 
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